What question did this study set out to answer?

The aim is to develop engineered E. coli for targeted immune engagement in cancer therapy.

Reprogramming Non-Pathogenic E. Coli Surface for Enhanced Cancer Immune Therapies

View Full Paper

Ask AI

Bookmark

Authors

This research demonstrates engineered E. coli enhances anti-tumor immunity in cancer models, suggesting new therapeutic avenues.

The aim is to develop engineered E. coli for targeted immune engagement in cancer therapy.
Engineered E. coli to display scFvs targeting TAAs and immune receptors.
In vitro co-culture with primary human T or NK cells assessed binding and activation.
Mice with tumor models received LIME treatment with potential combination therapies.
Tumor growth and immune activation were analyzed using flow cytometry and ELISA.
LIME activated human T or NK cells and improved tumor cell elimination.
CD19 LIME achieved ∼34% cure in A20-bearing mice; ∼80% with anti-PD-1.
Mesothelin LIME significantly slowed KPC tumor growth with co-treatment.
DLL3 LIME showed better tumor control than Tarlatamab.

Yang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark